Phase 3 Mantle Cell Lymphoma Clinical Trials
8 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–8 of 8 trials
Recruiting
Phase 3
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Mantle Cell Lymphoma
BeOne Medicines300 enrolled148 locationsNCT06742996
Recruiting
Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Chronic Lymphocytic LeukemiaMantle Cell LymphomaFollicular Lymphoma+1 more
Janssen Research & Development, LLC700 enrolled174 locationsNCT01804686
Recruiting
Phase 3
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology421 enrolled233 locationsNCT05976763
Recruiting
Phase 3
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Mantle Cell Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.394 enrolled2 locationsNCT07377578
Recruiting
Phase 3
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
Mantle Cell Lymphoma
InnoCare Pharma Inc.476 enrolled39 locationsNCT06363994
Recruiting
Phase 3
Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
Mantle Cell Lymphoma (MCL)
Ruijin Hospital78 enrolled1 locationNCT06496308
Recruiting
Phase 3
A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma
Treatment-naїve Mantle Cell Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.356 enrolled22 locationsNCT05051891
Recruiting
Phase 3
ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma
Mantle Cell Lymphoma
Prof. Dr. M. Dreyling (co-chairman)870 enrolled112 locationsNCT02858258